Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111306 · ClinicalTrials.gov registry record · Phase 3
Study of Epratuzumab in Systemic Lupus Erythematosus
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT00111306 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 510 participants.
The verdict
NCT00111306, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
Interventions
- DRUG epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111306
The ClinicalTrials.gov registry entry for NCT00111306 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epratuzumab is the first listed.
NCT00111306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111306 about?
NCT00111306 is a clinical study titled "Study of Epratuzumab in Systemic Lupus Erythematosus". The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
What is the current status of trial NCT00111306?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2005-06. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00111306?
The interventions under investigation include: epratuzumab (DRUG).
Who is sponsoring clinical trial NCT00111306?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.